# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, dri...
Piper Sandler analyst David Westenberg maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target fro...
The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnos...
Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $153 to $...
Quest Diagnostics reported a second-quarter adjusted EPS of $2.35, surpassing the consensus of $2.34. Sales rose 2.5% year-over...
Tuesday's Wall Street session was mixed, with small-caps outperforming large-caps as investors awaited earnings from Alphab...
The market mood turned jittery after Monday’s rebound, with index futures trading on either side of the unchanged line early Tu...